Table 1 Demographic and clinical characteristics
From: Telemedicine for the management of diabetic patients in a high-complexity Latin American hospital
Variable | Diabetes Mellitus | |
|---|---|---|
Type 1, n = 117 | Type 2, n = 546 | |
Age, years* | 20 (15–32) | 67 (58–75) |
Time since diabetes diagnosis, years* | 8 (3–15) | 9 (3–15) |
Area of residence (%) | ||
Urban | 81 (69.2) | 443 (81.1) |
Rural | 4 (3.4) | 17 (3.1) |
History of hypertension (%) | 8 (6.8) | 315 (57.6) |
Microvascular and macrovascular complications (%) | ||
No | 94 (80.34) | 348 (63.73) |
Yes | 18 (15.38) | 174 (31.86) |
Chronic kidney disease | 13 (11.11) | 76 (13.91) |
Neuropathy | 11 (9.40) | 37 (6.77) |
Retinopathy | 9 (7.69) | 42 (7.69) |
Peripheral vascular disease | 1 (0.85) | 16 (2.93) |
Coronary artery disease | 0 | 72 (13.18) |
Antidiabetic drugs (%) | ||
No | 0 | 33 (6.04) |
Yes | 117 (100) | 512 (93.77) |
Metformin | 8 (6.83) | 379 (69.41) |
Sulfonylureas | 0 | 12 (2.19) |
Dipeptidyl peptidase 4 (DPP-4) inhibitors | 4 (3.41) | 204 (37.36) |
Insulin | 110 (94.01) | 176 (32.23) |
GLP-1 analog | 7 (6) | 67 (12.27) |
Sodium-glucose cotransporter (SGLT2) inhibitors | 13 (11.1) | 198 (36.2) |